Edition:
United Kingdom

People: DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

147.72USD
8:21pm BST
Change (% chg)

$-3.08 (-2.04%)
Prev Close
$150.80
Open
$150.83
Day's High
$151.63
Day's Low
$147.01
Volume
248,923
Avg. Vol
452,556
52-wk High
$157.50
52-wk Low
$90.62

Balo, Andrew 

Mr. Andrew K. Balo serves as Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development of DexCom Inc. He has served as our Executive Vice President of Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development since May 2016. From January 2015 until April 2016 Mr. Balo served as our Executive Vice President, Clinical, Regulatory and Quality. From March 2008 to January 2015, Mr. Balo served as our Senior Vice President of Clinical and Regulatory Affairs, and from February 2002 to March 2008, served as our Vice President of Clinical and Regulatory Affairs. From June 1999 to February 2002, Mr. Balo served as Vice President, Regulatory and Clinical Affairs of Innercool Therapies, Inc., a medical technology company. Mr. Balo has held several positions at St. Jude Medical including Clinical, Vice President, Quality, Regulatory and Clinical Affairs and was an officer of the company. Mr. Balo received a B.S. from the University of Maryland.

Basic Compensation

Total Annual Compensation, USD 834,567
Restricted Stock Award, USD 2,317,820
Long-Term Incentive Plans, USD --
All Other, USD 22,251
Fiscal Year Total, USD 3,174,640

Options Compensation

  Quantity Market Value
Exercisable 86,405 1,202,080.00
Unexercisable 127,199 1,350,670.00
Exercised 3,927 220,117.00
Name Fiscal Year Total

Kevin Sayer

9,554,120

Quentin Blackford

3,391,640

Jake Leach

--

Donald Abbey

2,919,160

Andrew Balo

3,174,640

Richard Doubleday

3,207,460
As Of  31 Dec 2018